2019
Temozolomide in grade III neuroendocrine neoplasms (G3 NENs): A multicenter retrospective review.
Chan D, Bergsland E, Chan J, Gadgil R, Halfdanarson T, Hornbacker K, Kelly V, Kunz P, McGarrah P, Raj N, Reidy D, Thawer A, Whitman J, Wu L, Singh S. Temozolomide in grade III neuroendocrine neoplasms (G3 NENs): A multicenter retrospective review. Journal Of Clinical Oncology 2019, 37: 321-321. DOI: 10.1200/jco.2019.37.4_suppl.321.Peer-Reviewed Original ResearchTreatment failureG3 NENRetrospective reviewDose reduction/discontinuationBest radiological responseLocal pathology reportsMulticentre retrospective reviewOptimal systemic treatmentProspective confirmatory trialMedian TTFMulticenter retrospective reviewReduction/discontinuationBetter response rateViable treatment optionGastroenteropancreatic NENRadiologic responseStable diseasePrimary endpointRECIST criteriaAdverse eventsOverall survivalPartial responseProgressive diseaseRadiological responseSystemic treatment
2016
Chemotherapy for Elderly Ovarian Cancer Patients
Muralikrishnan S, Hatzis C, Katz A, Santin A, Schwartz PE, Abu-Khalaf MM. Chemotherapy for Elderly Ovarian Cancer Patients. Gynecology & Obstetrics 2016, 69: 1-5. PMID: 27695647, PMCID: PMC5042145, DOI: 10.4172/2161-0932.1000397.Peer-Reviewed Original ResearchPrimary ovarian cancerOvarian cancerYears of ageDose reductionDose reduction/discontinuationElderly ovarian cancer patientsPaclitaxel 175mg/Standard intravenous chemotherapyYale Cancer CenterAdditional prospective studiesReduction/discontinuationOvarian cancer patientsDifferent treatment modalitiesSignificant adverse effectsAUC 5Chemotherapy discontinuationIntravenous chemotherapyTreatment discontinuationHazard ratioStandard chemotherapyPrescribed regimenProspective studyRetrospective studyCancer CenterCancer patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply